A detailed history of Federation Des Caisses Desjardins Du Quebec transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Federation Des Caisses Desjardins Du Quebec holds 40 shares of AUPH stock, worth $324. This represents 0.0% of its overall portfolio holdings.

Number of Shares
40
Previous 40 -0.0%
Holding current value
$324
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$4.93 - $9.31 $197 - $372
40 New
40 $200,000
Q1 2022

Aug 14, 2024

BUY
$10.05 - $22.48 $2,010 - $4,496
200 Added 500.0%
240 $2.97 Million
Q4 2021

Aug 30, 2024

SELL
$17.78 - $33.08 $38,280 - $71,221
-2,153 Reduced 98.18%
40 $915,000
Q3 2021

Aug 30, 2024

SELL
$10.93 - $23.55 $3,279 - $7,065
-300 Reduced 12.03%
2,193 $48.5 Million
Q2 2021

Aug 30, 2024

BUY
$10.0 - $14.52 $24,530 - $35,617
2,453 Added 6132.5%
2,493 $32.2 Million
Q3 2020

Aug 30, 2024

SELL
$13.19 - $16.66 $13 - $16
-1 Reduced 0.05%
2,193 $32 Million
Q2 2020

Aug 30, 2024

BUY
$14.12 - $18.33 $14 - $18
1 Added 0.05%
2,194 $35.2 Million
Q1 2020

Aug 30, 2024

BUY
$11.34 - $21.46 $8,845 - $16,738
780 Added 55.2%
2,193 $31.4 Million
Q4 2019

Aug 30, 2024

SELL
$3.88 - $21.42 $3,104 - $17,136
-800 Reduced 36.15%
1,413 $28.3 Million
Q1 2019

Aug 30, 2024

SELL
$6.06 - $7.64 $18,180 - $22,920
-3,000 Reduced 57.55%
2,213 $14.2 Million
Q4 2018

Aug 30, 2024

BUY
$5.08 - $6.83 $26,278 - $35,331
5,173 Added 12932.5%
5,213 $34 Million
Q1 2018

Aug 30, 2024

BUY
$4.85 - $5.99 $6,644 - $8,206
1,370 Added 35.23%
5,259 $27.3 Million
Q4 2017

Aug 30, 2024

BUY
$4.53 - $7.09 $17,214 - $26,942
3,800 Added 4269.66%
3,889 $17.7 Million
Q1 2017

Aug 30, 2024

BUY
N/A
49
89 $651,000

Others Institutions Holding AUPH

About Aurinia Pharmaceuticals Inc.


  • Ticker AUPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,892,000
  • Market Cap $1.15B
  • Description
  • Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...
More about AUPH
Track This Portfolio

Track Federation Des Caisses Desjardins Du Quebec Portfolio

Follow Federation Des Caisses Desjardins Du Quebec and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.